Cabaletta Bio, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steven A. Nichtberger
- Full Time Employees
- 161
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2929 Arch Street Philadelphia PA United States of America 19104
- IPO Date
- Oct 25, 2019
- CIK
- 0001759138
- Website
- cabalettabio.com
- Similar Companies
- Business
- Cabaletta Bio, Inc. (Nasdaq: CABA) is a clinical-stage biotechnology company that develops and launches targeted cell therapies for patients with autoimmune diseases using its Cabaletta Approach to B cell Ablation (CABA) platform, which encompasses the CARTA strategy featuring rese-cel (resecabtagene autoleucel, formerly CABA-201), a fully human 4-1BB-containing CD19 chimeric antigen receptor (CAR) T cell therapy designed for transient, deep depletion of CD19-positive B cells to enable immune system reset; and the CAART strategy including DSG3-CAART for mucosal pemphigus vulgaris, MuSK-CAART for MuSK antibody-positive myasthenia gravis, and earlier-stage candidates such as DSG3/1-CAART for pemphigus and FVIII-CAART for hemophilia A. Rese-cel, the lead candidate, is evaluated in the ongoing Phase 1/2 RESET clinical program across systemic lupus erythematosus (including lupus nephritis), myositis (dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy), systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris, with FDA Fast Track and Regenerative Medicine Advanced Therapy designations in select indications. Founded in 2017 and headquartered at 2929 Arch Street, Suite 600, Philadelphia, Pennsylvania, the company operates primarily in the United States with global clinical trial sites and partnerships with contract development and manufacturing organizations including Cellares to scale production capacity beyond 100 doses annually of rese-cel. Recent developments include positive Phase 1/2 data presented at ACR Convergence 2025 showing all eligible myositis patients achieving moderate or major total improvement score responses off immunomodulators at week 16, prompting initiation of a 14-patient DM/ASyS registrational cohort this quarter with FDA-aligned design; transformative responses in systemic sclerosis patients off all immunosuppressants; strong lupus outcomes with seven of eight patients achieving remission or renal response, leading to expansion of the RESET-SLE trial with a no-preconditioning dose-escalation cohort and initial data expected in 2026; and planned FDA alignment on registrational designs for systemic sclerosis and lupus by year-end 2025 and myasthenia gravis in early 2026, alongside expanded enrollment in RESET-PV for pemphigus vulgaris.
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Cabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen Conference
Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now?
Cabaletta Bio: Do You Buy With The Insiders?